期刊文献+

他克莫司的临床应用评价 被引量:6

Evaluation on The Clinical Application of Tacrolimus
下载PDF
导出
摘要 目的:对他克莫司的药动学参数和不良反应等进行评价,为临床合理用药、个体化给药提供有益的信息和依据。方法:查阅他克莫司相关文献,对资料中的药物发生机制和常用药物进行分组,综合评价其临床应用。结果:他克莫司治疗窗窄、生物利用度低、个体差异大、联用时出现不良反应的几率较高。结论:临床上应高度重视他克莫司的合理使用,进行血液浓度监测应综合考虑联合用药等因素,实施个体化给药,保障用药安全。 OBJECTIVE: To evaluate the pharmacokinetic parameters and adverse reactions of tacrolimus so as to provide beneficial references for clinical rational drug use and individualized treatment of this drug.METHODS: By reviewing the relevant literature of tacrolimus,the commonly used medicines were grouped according to the drug interaction mechanism and then their clinical application was evaluated comprehensively.RESULTS: The use of tacrolimus was characterized by narrow therapeutic window,low bioavailability,great individual differences,and high probability of adverse drug reactions when used in drug combination.CONCLUSION: Great importance should be attached to the clinical rational use of tacrolimus.The factor of drug combination should be taken into consideration during monitoring of its blood concentration.Individualized administration of tacrolimus should be recommended to ensure medication safety.
机构地区 解放军第
出处 《中国医院用药评价与分析》 2012年第4期292-295,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 他克莫司 基因多态性 药物相互作用 个体化给药 Tacrolimus Gene polymorphism Drug interactions Individual treatment
  • 相关文献

参考文献17

  • 1Kameda G, Kramm C, Stege H, et al. Unexpected high serum levels of tacrolimus after a single topical application in an infant[J]. J Pediatr ,2003 ,143 (2) :280.
  • 2Teshima D, Ikesue H, Itoh Y, et al. Increased topical tacrolimus absorption in generalized leukemic erythroderma [ J ]. Ann Pharmacother ,2003,37 (10) : 1444.
  • 3Bekersky I, Dressler D, Mekki QA. Effect of low-and highfat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects [ J ]. J Clin Pharmacol,2001 ,41 (2) : 176.
  • 4Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus : a comparison across ethnic groups [ J ]. Clin Pharmacol Ther,2001,69( 1 ) :24.
  • 5Venkataramanan R, Shaw LM, Sarkozi L, et al. Ctinical utility of monitoring tacrolimus blood concentrations in liver transplant patients [ J ]. J Clin Pharmacol, 2001,41 (5) :542.
  • 6Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmaeokinetics of the ealeineurin inhibitors eyclosporine and tacrolimus[ J ]. Clin Pharrnacol Ther ,2003,74(3) :245.
  • 7Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3AS, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients [ J ]. Pharmacogenet C, enomics, 2006,16(9) :659.
  • 8侯明明,宋洪涛,王庆华,杨顺良,谭建明.肾移植患者CYP3A5*3基因多态性对他克莫司血药浓度/剂量比和疗效的影响[J].中国医院药学杂志,2010,30(4):313-316. 被引量:30
  • 9FDA. Alert for healthcare professionals : tacrolimus ( marketed as Protopic )03/05 [ EB/OL]. http://www, fda. gov/cder/ drug/InfoSheets/HCP/ProtopicHCP.
  • 10Winkler M, Schulze F, Jost U, et al. Anaemia associated with FK 506 immunosuppression [ J ]. Lancet, 1993,341 (8851) :1035.

二级参考文献4

共引文献29

同被引文献80

  • 1徐芳,翟所迪,胡永芳.他克莫司发生药物相互作用的分子机制[J].中国药学杂志,2007,42(13):965-968. 被引量:16
  • 2Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants[J]. Pharmacotherapy, 2006, 26(12), 1730-1744.
  • 3Tintillier M, Kirch L, Goffin E, et al. Interaction between vorieonazole and tacrolimus in a kidney, transplanted patient[J]. Nephrol Dial Transplant, 2005, 20(3): 664-665.
  • 4Chang HH, Lee NY, Ko WC, et al. Voriconazole inhibition of metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis[J]. Int J Infect Dis. 2010, 14(4): e348-350.
  • 5Capone D, Tarantino G, Gentile A, et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient[J]. J Clin Pharrn Ther, 2010, 35(1): 121-124.
  • 6Walia A, Schumann R. The evolution of liver transplantation practices[J]. Curr Opin Organ Transplant, 2008,13(3):275- 279.
  • 7Shapiro R. Low toxicity immunosuppressive protocols in re- nal transplantation[J]. Keio J Med, 2004,53(1):18-22.
  • 8Fung J J, Starzl TE.FK506 in solid organ transplantation[J]. Ther Drug Monit, 1995, 17(6):592-595.
  • 9Spada M, Corno V, Colledan M, et,al. Rejection and tacroli- mus conversion therapy in paediatric liver transplantation[J].Transpl Int, 2000,13 (Suppl 1 ) 341-344.
  • 10Van HJP,Christiaans MH. Use.of.tacrolimus.in.renalrans- plantation[J].Transplant Proc, 1999,31 (8): 3298-3299.

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部